28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) - Archive ouverte HAL Access content directly
Journal Articles Journal of The American Academy of Dermatology Year : 2021

28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

(1) , (2) , (3) , , (4) , , (5) , (6) , (7) , (8) , (9)
1
2
3
4
5
6
7
8
9
Not file

Dates and versions

hal-03853030 , version 1 (15-11-2022)

Identifiers

Cite

Andrew Blauvelt, Andreas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong, et al.. 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). Journal of The American Academy of Dermatology, 2021, 85 (3), pp.AB177. ⟨10.1016/j.jaad.2021.06.723⟩. ⟨hal-03853030⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More